Savage Brian 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 6, 2026

AI-generated summary of this filing

Updated Mar 6, 2026

TEVA Savage Brian (Interim CLO) Receives Award, Sells 2,675 Shares

What Happened

Brian Savage, Interim Chief Legal Officer of Teva Pharmaceutical (TEVA), had restricted share units (RSUs) convert/settle and an award recorded on March 4, 2026. The filing shows an award/acquisition of 11,280 shares and conversion/settlement entries for vested RSU tranches. To cover tax withholding, Savage sold 2,675 shares in open-market transactions for total proceeds of $86,843 (reported weighted average price $32.46).

Key Details

Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (timely).
Sales: 1,489 shares sold for $48,340 and 1,186 shares sold for $38,503; weighted average price $32.46; individual trade prices ranged $32.095–$33.30 (footnote).
Award/settlement: Filing shows RSU conversion/award activity (listed as derivative conversions (M) and an award (A) for 11,280 shares; several derivative disposals are shown at $0.00 reflecting net/derivative settlement).
Tax withholding: Footnote indicates the shares sold were required to be sold to cover tax withholding on RSU vesting (routine withholding); derivative disposals at $0.00 reflect net-settlement/withholding.
Shares owned after transaction: not specified in the publicly provided excerpt of the filing.
Codes explained: S = open-market sale; M = conversion/exercise of a derivative (here, RSU settlement); A = award/grant; F notes give vesting history for the RSUs.

Context

This appears to be a routine RSU vesting and settlement event, not an open-market purchase (no new buy). Part of the vested shares were sold to satisfy tax withholding obligations (common practice), while the remainder were retained. Derivative/zero-dollar disposition lines reflect net settlement or shares withheld for taxes rather than a market sale.

Form 4

Period: 2026-03-04

Interim Chief Legal Officer

Transactions

Exercise/Conversion
Ordinary Shares
[F1][F2]
2026-03-04+4,744→ 7,670 total
Sale
Ordinary Shares
[F1][F3][F4]
2026-03-04$32.46/sh−1,489$48,340→ 6,181 total
Exercise/Conversion
Ordinary Shares
[F1][F2]
2026-03-04+3,466→ 9,647 total
Sale
Ordinary Shares
[F1][F3][F4]
2026-03-04$32.46/sh−1,186$38,503→ 8,461 total
Exercise/Conversion
Restricted Share Units
[F2][F5][F1]
2026-03-04−4,744→ 0 total
→ Ordinary Shares (4,744 underlying)
Exercise/Conversion
Restricted Share Units
[F2][F6][F1]
2026-03-04−3,766→ 7,534 total
→ Ordinary Shares (3,766 underlying)
Award
Restricted Share Units
[F2][F7][F1]
2026-03-04+11,280→ 11,280 total
→ Ordinary Shares (11,280 underlying)

Footnotes (7)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
[F3]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F5]Restricted share units were granted on March 4, 2022, with 4,741 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 4,744 vested on March 4, 2026.
[F6]Restricted share units were granted on March 4, 2024, with 3,766 vested on each of March 4, 2025 and March 4, 2026, 3,766 vesting on March 4, 2027, and 3,768 vesting on March 4, 2028.
[F7]Restricted share units were granted on March 4, 2026, with 2,820 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030.

Signature

/s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage|2026-03-06

1 file